144 related articles for article (PubMed ID: 14626493)
1. Eicosanoids in cirrhosis and portal hypertension.
Birney Y; Redmond EM; Sitzmann JV; Cahill PA
Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):3-18. PubMed ID: 14626493
[TBL] [Abstract][Full Text] [Related]
2. Endothelial dysfunction in cirrhosis and portal hypertension.
Cahill PA; Redmond EM; Sitzmann JV
Pharmacol Ther; 2001 Mar; 89(3):273-93. PubMed ID: 11516480
[TBL] [Abstract][Full Text] [Related]
3. Arachidonic acid metabolites and endothelial dysfunction of portal hypertension.
Sacerdoti D; Pesce P; Di Pascoli M; Brocco S; Cecchetto L; Bolognesi M
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():80-90. PubMed ID: 26072731
[TBL] [Abstract][Full Text] [Related]
4. Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future--Georges Brohée Lecture.
Laleman W
Acta Gastroenterol Belg; 2009; 72(1):9-16. PubMed ID: 19402365
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
Gatta A; Bolognesi M; Merkel C
Mol Aspects Med; 2008; 29(1-2):119-29. PubMed ID: 18036654
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology of portal hypertension.
Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
Sacerdoti D; Gatta A; McGiff JC
Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
[TBL] [Abstract][Full Text] [Related]
8. Portal hypertension: state of the art.
Gatta A; Sacerdoti D; Bolognesi M; Merkel C
Ital J Gastroenterol Hepatol; 1999 May; 31(4):326-45. PubMed ID: 10425579
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
10. Cooperation of liver cells in health and disease.
Kmieć Z
Adv Anat Embryol Cell Biol; 2001; 161():III-XIII, 1-151. PubMed ID: 11729749
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamics in the isolated cirrhotic liver.
Zipprich A
J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
Thabut D; Shah V
J Hepatol; 2010 Nov; 53(5):976-80. PubMed ID: 20800926
[TBL] [Abstract][Full Text] [Related]
13. [Morphofunctional rearrangement of the hepatic vasculature in the pathogenesis of portal hypertension in liver cirrhosis].
Garbuzenko DV
Ter Arkh; 2014; 86(2):90-5. PubMed ID: 24772515
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular basis of portal hypertension.
Shah V
Clin Liver Dis; 2001 Aug; 5(3):629-44. PubMed ID: 11565134
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Deng W; Zhu Y; Lin J; Zheng L; Zhang C; Luo M
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():67-74. PubMed ID: 28822809
[TBL] [Abstract][Full Text] [Related]
16. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
Shah V
J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
[TBL] [Abstract][Full Text] [Related]
20. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
